Collaborative Arrangements (Tables)

12 Months Ended

Dec. 31, 2022

Collaborative Arrangements [Abstract]

Collaborative Arrangements

Summarized financial information related to this collaboration is as follows:

Years Ended December 31	2022		2021		2020
Alliance revenue - Lynparza	$	1,116	$	989	$	725
Alliance revenue - Koselugo	54		29		8
Total alliance revenue	$	1,170	$	1,018	$	733
Cost of sales (1)	492		167		247
Selling, general and administrative	185		178		160
Research and development	106		120		133
December 31	2022		2021
Receivables from AstraZeneca included in Other current assets	$	303	$	271
Payables to AstraZeneca included in Trade accounts payable and Accrued and other current liabilities (2)	123		415
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)	600		—

(1)    Represents amortization of capitalized milestone payments. Amounts in 2022 and 2020 include $250 million and $106 million, respectively, of cumulative amortization catch-up expense.

(2)    Includes accrued milestone payments.

Summarized financial information related to this collaboration is as follows:

Years Ended December 31	2022		2021		2020
Alliance revenue - Lenvima	$	876	$	704	$	580
Cost of sales (1)	212		195		271
Selling, general and administrative	158		127		73
Research and development	136		173		185
December 31	2022		2021
Receivables from Eisai included in Other current assets	$	214	$	200
Payables to Eisai included in Accrued and other current liabilities (2)	—		625

(1)     Represents amortization of capitalized milestone payments.

(2)     Represents accrued milestone payments.

Summarized financial information related to this collaboration is as follows:

Years Ended December 31	2022		2021		2020
Alliance revenue - Adempas/Verquvo	$	341	$	342	$	281
Net sales of Adempas recorded by Merck	238		252		220
Net sales of Verquvo recorded by Merck	22		7		—
Total sales	$	601	$	601	$	501
Cost of sales (1)	210		424		196
Selling, general and administrative	153		126		47
Research and development	75		53		63
December 31	2022		2021
Receivables from Bayer included in Other current assets	$	143	$	114
Payables to Bayer included in Accrued and other current Liabilities (2)	80		472

(1)    Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense.

(2)    Amount as of December 31, 2021 includes accrued milestone payment.

Summarized financial information related to this collaboration is as follows:

Years Ended December 31	2022		2021		2020
Net sales of Lagevrio	$	5,684	$	952	$	—
Cost of sales (1)(2)	3,038		502		17
Selling, general and administrative (2)	147		37		6
Research and development (2)(3)	88		137		349
December 31	2022		2021
Payables to Ridgeback included in Accrued and other current liabilities (4)	$	348	$	283

(1)    Includes royalty expense and amortization of capitalized milestone payments.

(2)    Expenses in all periods now include an allocation for overhead charges.

(3)    Amount in 2020 includes upfront payment.

(4)    Includes accrued royalty and milestone payments.